DUBLIN--(BUSINESS WIRE)--Sep 11, 2018--The "Cutaneous Squamous cell Carcinoma (CsCC) - Epidemiology Insights to 2025" report has been added to ResearchAndMarkets.com's offering.

Cutaneous Squamous cell Carcinoma (CsCC) - Epidemiology Forecast, 2025 provides an overview of the epidemiology trends of Cutaneous Squamous cell Carcinoma (CsCC) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Insulin Resistance.

The report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Insulin Resistance. The report contains the targeted patient populations and the forecast methodology.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by a team of industry experts.

Key Coverage and Benefits:

The report includes the prevalent population and how will it change over the next eight years. Coverage of key Cutaneous Squamous cell Carcinoma (CsCC) sub-populations and its prevalent or incident cases Prevalent or incident cases segmented by age and sex. The key differences in epidemiology patterns across the seven market segments.

Key Topics Covered:

1. Report Introduction

2. Snapshot Of Total Prevalent Or Incident Cases By 7 Mm

3. Executive Summary

4. Cutaneous Squamous Cell Carcinoma (Cscc) Overview

5. Risk Factors Associated With Cutaneous Squamous Cell Carcinoma (Cscc)

6. Disease Burden & Unmet Need In The Market

7. Epidemiology And Patient Populations

8. Prevalent & Incident Cases By 7 Mm-2015-2025

9. Key Takeaways

10. Appendix

11. Report Methodology

For more information about this report visit https://www.researchandmarkets.com/research/nl3frf/global_cutaneous?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005310/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Skin Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/11/2018 04:30 AM/DISC: 09/11/2018 04:30 AM